AMPKi overcomes the paradoxical activation of CRAF driven by RAF inhibitors through blocking the 14-3-3 binding to its carboxyl-terminus
J. Yuan, W. H. Ng, J. Yap, B. Chia, X. Huang, M. Wang, J. Hu
This study identifies AMPKi as a compound that blocks 14-3-3 binding to CRAF, overcoming RAF inhibitor resistance by preventing paradoxical CRAF activation in cancer cells.
bioRxiv · Jan 30, 2018Cancer Biology